摘要胰腺导管腺癌在消化系统肿瘤中的发病率逐年上升，其恶性程度高，患者预后差，5年生存率不足8%。胰腺癌对放化疗不敏感，寻找新的药物治疗方式十分重要。近年来，分子靶向治疗在血液系统恶性肿瘤、非小细胞肺癌和黑色素瘤等疾病中取得了一定进展，在胰腺癌中大量的作用靶点亦有所尝试，如基因突变靶点、重要信号通路靶点、受体靶点等。这些靶向药物的单独或联合使用在临床前模型和部分临床试验中显示出良好效果，部分方案已成为胰腺癌患者的规范治疗方案，尚未进行大规模临床试验的其他方案也为未来胰腺癌靶向治疗提供了多种潜在可能性。

abstractsThe incidence of pancreatic ductal adenocarcinoma(PDAC) is increasing year by year among digestive system tumors.It has a high degree of malignancy and a poor prognosis.Its five-year survival rate is less than 8%.Traditional radiotherapy and chemotherapy are not sensitive to pancreatic cancer,so finding a new drug is the future hope for pancreatic cancer.In recent years,molecular targeted therapy has made obvious progress in diseases such as hematological malignancies,non-small cell lung cancer and melanoma,and a large number of targets have been tried in pancreatic cancer, for example, gene mutation targets, important signaling pathway targets, receptor targets, etc. The use of these targeted drugs alone or in combination has shown good results in preclinical models and some clinical trials, and some treatment have been standardized for patients with pancreatic cancer, while other options that have not yet been tested in large-scale clinical trials also offer a variety of potential possibilities for future targeted treatments for pancreatic cancer.